Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response-Reference-Cited by-同舟云学术

Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response

Published:2022-06-29 Issue:13 Volume:65 Page:9230-9252
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yang Ming-Hsiu¹,Russell Jamie L.²,Mifune Yuto¹,Wang Ying²,Shi Hexin²,Moresco Eva Marie Y.²,Siegwart Daniel J.³^ORCID,Beutler Bruce²,Boger Dale L.¹^ORCID

Affiliation:

1. Department of Chemistry and the Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States

2. Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

3. Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Funder

National Cancer Institute

National Institute of Allergy and Infectious Diseases

Cystic Fibrosis Foundation Therapeutics

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link